Company intelligence / Profile preview
PendreaBio
State College, Pennsylvania, United Statespendreabio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Completed a Phase 1 study of C6 Ceramide NanoLiposome in patients with advanced solid tumors. Currently has an active Phase 1 clinical trial that started on June 1, 2024
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- NanoliposomesNanoJackets (calcium phosphate nanoparticles)RNA therapeutics (siRNA, mRNA, miRNA)Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on PendreaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PendreaBio.